Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes.
about
Management of patients with biochemical recurrence after local therapy for prostate cancerSalvage local therapy for radiation-recurrent prostate cancer - where are we?PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure.Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer.Impact of folate intake on prostate cancer recurrence following definitive therapy: data from CaPSUREā¢.Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry.CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavorAchieving the 'bifecta' using salvage cryotherapy for locally recurrent prostate cancer: analysis of the Cryo On-Line Data (COLD) registry data.Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression.Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancerIonizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patientsVegetable and fruit intake after diagnosis and risk of prostate cancer progression.Costs of early adjuvant radiation therapy after radical prostatectomy: a decision analysis.Targeted prostate biopsy and MR-guided therapy for prostate cancer.Management of biochemical recurrence after primary localized therapy for prostate cancerReview of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.Low detectable prostate specific antigen after radical prostatectomy--treat or watch?The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer.Preoperative erectile function and the pathologic features of prostate cancer.Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.The relation between age and androgen deprivation therapy use among men in the Medicare population receiving radiation therapy for prostate cancerSalvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experienceAndrogen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.Circulating microRNAs predict biochemical recurrence in prostate cancer patients.Salvage HIFU for recurrent prostate cancer after radiotherapy.RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study.Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score.Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets.High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after radiotherapyIs high-dose leuprorelin acetate effective and safe in asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial.Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemopreventionSalvage robotic assisted laparoscopic radical prostatectomy: indications and outcomes.Robotic high-intensity focused ultrasound for prostate cancer: what have we learned in 15 years of clinical use?Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer.Current status of salvage robot-assisted laparoscopic prostatectomy for radiorecurrent prostate cancer.[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
P2860
Q26849220-59E87EC0-6BF3-45E8-B229-933C326BC721Q28065991-B421B5AB-9058-45AD-B13F-2B2641EFB95BQ30365461-20F3F5AB-A42F-41A7-97A6-EDD4B35780E7Q30376901-4244E4EA-2333-46E6-B09C-EAE8798D8F41Q30671456-89F8EAC8-5A33-46AF-89CC-CF00EE398A58Q30857429-64D8D7D7-BE03-4703-AE2C-ECB217F0EDC1Q33897765-031BEBC2-05FA-4C02-B787-F0FC5BCF6D6DQ33910774-219CF23B-2A80-45C5-8A5F-9D448B1D3285Q34047223-8811269A-B89E-45AC-A622-44A15BD4F25AQ34228828-19E0B1EC-1233-405E-BC22-A80BCADB21DFQ34288796-BFA50E76-45B0-404F-A9F2-2CA98B426893Q35093069-E3D0BB38-3F85-45F4-BFAA-C3BE2A31A3E3Q35120911-7436B5AD-8D8F-4ED3-9192-12BF64C66297Q35380936-DB49F968-ED38-4338-AED4-7B0F5F72881BQ35846299-A441DCED-642E-40E1-B1E1-80561A9C8EB6Q35902806-BDE6999B-F98A-41E6-AC6F-B47715BBBE35Q35933229-A41B5738-CF9C-4F6C-893C-47FDF2082E6EQ35981941-036307F5-D505-48DC-A716-BF2D241ED9A2Q36010923-26A2F0AF-89FF-4C8C-A0F0-508DB7AFB71AQ36100502-6297B383-2266-4947-B90A-603C773C2893Q36393776-5F76861D-E339-42D0-ABD8-A7280CE3F835Q36575795-9FD72D68-287B-4D01-9472-BB4C870FC17AQ36653022-5DAA0E6D-5CC3-41D2-B3A1-82759A2AFB66Q36665817-450701CA-AC60-442D-8BEF-400F94BA13B6Q36973533-A64BDECB-9ED7-4AA3-8676-FFD51FA20C72Q37034670-6195747D-C473-4D82-9977-F4A36332B272Q37081843-B7265114-B555-4339-8332-01B2912F99FCQ37293116-1D999E48-02D4-4FF6-B6FF-C5BAAF98439EQ37357942-2851F19B-F875-4797-A1E9-5C8012798223Q37575815-AB41B68E-E824-45E6-B37F-7678E67FEBC7Q37581405-FD4BEB6C-5A0F-45EC-8353-11513BA5E302Q37583804-A32BC526-A95B-46BF-BF85-EB421708D288Q37603749-74D510DC-E1ED-4204-9271-5F16D2C9AB92Q37606746-8226E84F-F8EC-475F-9178-D45AAEB2C561Q37700962-2FC1CFF0-FF37-461D-8F59-D6F8536078EAQ37811992-02ED6D24-3112-4DB6-A25B-F72F7A15E069Q37856802-04A56738-2227-45DA-88D6-C94471644B52Q37968978-856D53CE-02E4-4988-A729-C60ADC497994Q37994994-6628B246-B83F-4EBE-AE32-E0B4930D061AQ38004182-99E9ADD8-C2F3-4D97-997B-98802621A4BD
P2860
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes.
description
2008 nĆ® lÅ«n-bĆ»n
@nan
2008幓ć®č«ę
@ja
2008幓å¦ęÆęē«
@wuu
2008幓å¦ęÆęē«
@zh-cn
2008幓å¦ęÆęē«
@zh-hans
2008幓å¦ęÆęē«
@zh-my
2008幓å¦ęÆęē«
@zh-sg
2008幓åøč”ęē«
@yue
2008幓åøč”ęē«
@zh
2008幓åøč”ęē«
@zh-hant
name
Treatment failure after primar ...... atterns of care, and outcomes.
@en
Treatment failure after primar ...... atterns of care, and outcomes.
@nl
type
label
Treatment failure after primar ...... atterns of care, and outcomes.
@en
Treatment failure after primar ...... atterns of care, and outcomes.
@nl
prefLabel
Treatment failure after primar ...... atterns of care, and outcomes.
@en
Treatment failure after primar ...... atterns of care, and outcomes.
@nl
P2093
P356
P1433
P1476
Treatment failure after primar ...... atterns of care, and outcomes.
@en
P2093
Badrinath R Konety
Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE)
Martin I Resnick
Natalia Sadetsky
Peter R Carroll
P304
P356
10.1002/CNCR.23161
P407
P577
2008-01-01T00:00:00Z